Perampanel as Adjunctive Therapy in Pediatrics With Partial Onset Seizures or Primary Generalized Tonic Clonic Seizures
Public ClinicalTrials.gov record NCT02849626. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
An Open-Label, Multicenter Study With an Extension Phase to Evaluate the Safety, Tolerability, and Exposure-Efficacy Relationship of Perampanel Oral Suspension When Administered as an Adjunctive Therapy in Pediatric Subjects (Age 4 to Less Than 12 Years) With Inadequately Controlled Partial-Onset Seizures or Primary Generalized Tonic Clonic Seizures
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is an open-label, multicenter study with an Extension Phase to evaluate the safety and tolerability of perampanel oral suspension when administered as an adjunctive therapy in children (ages 4 to less than \[\<\] 12 years) with inadequately controlled partial onset seizures (POS) or primary generalized tonic clonic (PGTC) seizures.
Study identification
- NCT ID
- NCT02849626
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 180 participants
Conditions and interventions
Eligibility (public fields only)
- Age range
- 4 Years to 12 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 16, 2016 (Actual)
- Primary completion
- Feb 5, 2019 (Actual)
- Completion
- Dec 6, 2021 (Actual)
- Last update posted
- Oct 28, 2022
2016 – 2021
United States locations
- U.S. sites
- 29
- U.S. states
- 22
- U.S. cities
- 28
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Facility #1 | Little Rock | Arkansas | — | — |
| Facility #1 | Palo Alto | California | — | — |
| Facility #1 | Aurora | Colorado | — | — |
| Facility #1 | Gulf Breeze | Florida | — | — |
| Facility #1 | Loxahatchee Groves | Florida | — | — |
| Facility #1 | Orlando | Florida | — | — |
| Facility #1 | Atlanta | Georgia | — | — |
| Facility #1 | Savannah | Georgia | — | — |
| Facility #1 | Boise | Idaho | — | — |
| Facility #1 | Chicago | Illinois | — | — |
| Facility #1 | Urbana | Illinois | — | — |
| Facility #1 | Ames | Iowa | — | — |
| Facility #1 | Wichita | Kansas | — | — |
| Facility #1 | Lexington | Kentucky | — | — |
| Facility #2 | Lexington | Kentucky | — | — |
| Facility #1 | New Orleans | Louisiana | — | — |
| Facility #1 | Duluth | Minnesota | — | — |
| Facility #1 | Kansas City | Missouri | — | — |
| Facility #1 | Henderson | Nevada | — | — |
| Facility #1 | Hackensack | New Jersey | — | — |
| Facility #1 | Voorhees Township | New Jersey | — | — |
| Facility #1 | Brooklyn | New York | — | — |
| Facility #1 | Winston-Salem | North Carolina | — | — |
| Facility #1 | Cleveland | Ohio | — | — |
| Facility #1 | Memphis | Tennessee | — | — |
| Facility #1 | Austin | Texas | — | — |
| Facility #1 | San Antonio | Texas | — | — |
| Facility #1 | Tacoma | Washington | — | — |
| Facility #1 | Milwaukee | Wisconsin | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 62 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02849626, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 28, 2022 · Synced Oct 30, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT02849626 live on ClinicalTrials.gov.